Clinical trials
Phase 2 Myelodysplastic Syndromes trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 3 |
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Active, not recruiting | 5 |
| Terminated | 5 |
| Recruiting | 3 |
| Unknown status | 2 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 8 |
| Fondazione Italiana Sindromi Mielodisplastiche-ETS | 4 |
| Associazione Qol-one | 3 |
| Celgene | 3 |
| Ciceri Fabio | 2 |
| Janssen Research & Development, LLC | 2 |
| Agios Pharmaceuticals, Inc. | 1 |
| Celgene Corporation | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| GlaxoSmithKline | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myelodysplastic Syndromes | 37 |
| Leukemia, Myeloid, Acute | 8 |
| Leukemia, Myelomonocytic, Chronic | 5 |
| Anemia | 2 |
| Anemia, Refractory, with Excess of Blasts | 2 |
| Iron Overload | 2 |
| Leukemia | 2 |
| Myeloproliferative Disorders | 2 |
| Thalassemia | 2 |
| Thrombocytopenia | 2 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.